PanTher Therapetics’ Sagittari platform brings a novel spin to traditional oncology drugs, helping deliver active ingredients to the tumor without affecting the bloodstream using methods inspired by cardiology interventions.
PanTher Reimagines Cardiology Interventions As Precision Oncology Platform
Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors.
More from Emerging Company Profiles
• By
Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.
• By
Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.
• By
Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.
• By
Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.
More from Start-Ups & SMEs
• By
The Biovelocita II fund is supported by the likes of Amgen, Bristol Myers Squibb and Pfizer
• By
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.